Abstract 2200
Background
Bone metastases (BM) are common in patients with solid tumours, especially breast, prostate and lung cancer. Patients with BM may experience skeletal-related events (SRE) including pathological fractures and spinal cord compression. Bisphosphonates and denosumab, known as SRE preventive agents (SPA), are indicated for patients with BM and are recommended by ESMO guidelines. However, data on the clinical use of these agents are lacking. The aim of this study was to estimate the proportion of SPA- and SRE-naïve patients receiving SPA treatments at SRE preventive doses following BM diagnosis.
Methods
Adult patients with solid tumours, a record of BM and no record of SPA treatment or an SRE before the first-recorded BM were identified from March 2011 to June 2016 in the Danish National Patient Registry or Danish Cancer Registry. The proportion of patients receiving hospital-administered SPA, identified via the Health Services Database of the Central Denmark Region, was calculated over the 6-month period after their first-recorded BM diagnosis along with the 95% confidence interval (CI). Follow-up was until death or December 31, 2016.
Results
A total of 2,556 eligible patients were included (m/f 1501/1055; median age 70 years (IQR 63–77). SPA treatment was recorded for 822 (32%) patients, mainly before the development of an SRE (86%, n = 706), in contrast to post-SRE (14%, n = 116). Across all solid tumours, a greater proportion of younger than older patients received SPA treatment. Receipt of SPA before an SRE varied by cancer site: lung (50%, 95% CI 46%–54%), breast (42%, 95% CI 37%–47%), prostate (3%, 95% CI 2%–5%), and other solid tumours (20%, 95% CI 18%–23%). Median [IQR] time from first-recorded BM diagnosis to first SPA before an SRE also varied by cancer site: breast (22 [7, 51] days), lung (6 [3, 26] days), prostate (43 [17, 57] days) and other solid tumours (24 [5, 44] days).
Conclusions
In this descriptive study, variations in the use of SPA for SRE prevention in routine clinical settings were observed across different solid tumours, warranting further cancer-specific investigations while accounting for patients’ characteristics.
Clinical trial identification
Amgen study 20160169.
Editorial acknowledgement
Legal entity responsible for the study
Amgen (Europe) GmbH.
Funding
Amgen (Europe) GmbH through an institutional grant; administered by Aarhus University.
Disclosure
J. Acquavella: Shareholder / Stockholder / Stock options; JA retired from Amgen in 2014. A.M. Seesaghur: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen; Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. R.K. Hernandez: Shareholder / Stockholder / Stock options, Full / Part-time employment: Amgen. V. Ehrenstein: Full / Part-time employment; VE is a salaried employee of Aarhus University and has nothing to declare. All other authors have declared no conflicts of interest.
Resources from the same session
5037 - CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features
Presenter: Olga Savelieva
Session: Poster Display session 1
Resources:
Abstract
5729 - Expression of mutant p53 affects cancer cell sensitivity to topotecan
Presenter: Rimma Mingaleeva
Session: Poster Display session 1
Resources:
Abstract
5725 - Breast cancer organoids a new tool for the prediction of drugs penetration and patient’outcome
Presenter: Giuseppina Roscigno
Session: Poster Display session 1
Resources:
Abstract
5680 - Aptamer-mediated exosomes detection for early breast cancer identification.
Presenter: Cristina Quintavalle
Session: Poster Display session 1
Resources:
Abstract
2460 - MicroRNA-181c promotes tamoxifen resistance in breast cancer cells via upregulation Akt/mTOR axis
Presenter: Alexander Scherbakov
Session: Poster Display session 1
Resources:
Abstract
3751 - Spatio-temporal separation of tumor infiltrating CD8+ T-cells and HER2/neu+ tumor cells in tumor-immune milieu of infiltrating ductal carcinoma of the breast
Presenter: Sandhya Sreedharan
Session: Poster Display session 1
Resources:
Abstract
4664 - Large genomic rearrangements in BRCA1 and BRCA2 genes in the Portuguese population.
Presenter: Joao Pinto
Session: Poster Display session 1
Resources:
Abstract
4611 - Non-BRCA1/2 hereditary breast and ovarian cancer: findings from a multidisciplinary program
Presenter: Ana Monteiro
Session: Poster Display session 1
Resources:
Abstract
5340 - Quantitative imaging and characterization of collagen patterns in high grade serous ovarian carcinoma (HGSOC)
Presenter: Ruby Huang
Session: Poster Display session 1
Resources:
Abstract
4209 - Semiquantitative assessment of vimentin expression in prostate cancer (PC)
Presenter: Marina Puchinskaya
Session: Poster Display session 1
Resources:
Abstract